Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Confident In Output From Its Revamped R&D Engine

This article was originally published in The Pink Sheet Daily

Executive Summary

Britain’s biggest drug maker updated the investment community on its pipeline prospects Dec. 3, outlining a timescale of three pipeline “waves” that will include pivotal clinical trial results on up to 14 medicines in the next two years.

Advertisement

Related Content

GSK R&D President Patrick Vallance On Increasing R&D Productivity: An Interview With PharmAsia News (Part 2 of 2)
GSK R&D President Patrick Vallance On Increasing R&D Productivity: An Interview With PharmAsia News (Part 1 of 2)
GSK Highlights Easy Pen Delivery Of Albiglutide As FDA Begins Review
Precision Medicine And The Advent Of The “Niche Buster”: An Interview With GSK’s Paolo Paoletti
GSK Highlights Easy Pen Delivery Of Albiglutide As FDA Begins Review
Investors See Pharma Promise In 2013, Look Past Patent Cliff
Scancell’s DNA Plasmid-Cancer Vaccine Shows Promise In Melanoma
Glaxo’s Emerging BRAF/MEK Melanoma Combo Threatens Roche’s Zelboraf
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
GSK Makes Clever Decision Choosing Witty As New CEO

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073678

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel